Prophylactic Efficacy of CD388, a Novel Drug–Fc Conjugate, in a Human Influenza A/H3N2 Virus Challenge Model: A Randomized, Controlled Phase 2a Study
CD388 was well-tolerated and demonstrated prophylactic activity against RT-qPCR-confirmed influenza infection in a human challenge study. The efficacy of CD388 in preventing influenza will be confirmed in larger studies. Clinical Trials Registration. ClinicalTrials.gov identifier: NCT05523089.
Authors
- Arun Anandakumar
- Shawn Flanagan (ORCID: https://orcid.org/0000-0003-0464-9301)
- Johan Vingerhoets
- Wilbert van Duijnhoven
- Sy-Shi Wang
- Isabel Gonçalves Silva (ORCID: https://orcid.org/0000-0002-5224-2357)
- Tristan Baguet (ORCID: https://orcid.org/0000-0002-1067-9374)
- Jorge Villacian
- Alice Tourneroche
- Ozlem Equils (ORCID: https://orcid.org/0000-0003-1399-7623)
- Roxana E. Rojas
- Alex Mann
- Antoinette Anger
Institutions
- Johnson & Johnson (United States) (US)
- hVIVO (United Kingdom) (GB)
- Johnson Engineering (United States) (US)
- Enzo Life Sciences (United States) (US)
- Johnson & Johnson (Australia) (AU)
- Cidara Therapeutics (United States) (US)
- Johnson & Johnson (Brazil) (BR)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1093/cid/ciaf465
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00